HRP20231584T1 - Postupak za podršku memorijskoj funkciji i/ili kognitivnoj funkciji - Google Patents
Postupak za podršku memorijskoj funkciji i/ili kognitivnoj funkciji Download PDFInfo
- Publication number
- HRP20231584T1 HRP20231584T1 HRP20231584TT HRP20231584T HRP20231584T1 HR P20231584 T1 HRP20231584 T1 HR P20231584T1 HR P20231584T T HRP20231584T T HR P20231584TT HR P20231584 T HRP20231584 T HR P20231584T HR P20231584 T1 HRP20231584 T1 HR P20231584T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- per
- vitamin
- use according
- uridine
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title claims 3
- 230000006386 memory function Effects 0.000 title claims 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 3
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 229930003268 Vitamin C Natural products 0.000 claims 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 2
- 229960001231 choline Drugs 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- 239000011669 selenium Substances 0.000 claims 2
- 229910052711 selenium Inorganic materials 0.000 claims 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 2
- 229940045145 uridine Drugs 0.000 claims 2
- 235000019154 vitamin C Nutrition 0.000 claims 2
- 239000011718 vitamin C Substances 0.000 claims 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims 1
- 208000024806 Brain atrophy Diseases 0.000 claims 1
- 239000004381 Choline salt Substances 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 229930003761 Vitamin B9 Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- -1 choline ester Chemical class 0.000 claims 1
- 235000019417 choline salt Nutrition 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 235000019159 vitamin B9 Nutrition 0.000 claims 1
- 239000011727 vitamin B9 Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (7)
1. Pripravak za uporabu u terapeutskom poboljšanju pamćenja i/ili kognitivne funkcije kod starijeg ljudskog subjekta starog najmanje 55 godina kojem je to potrebno, navedeni pripravak sadrži terapeutski učinkovite količine
(i) vitamin C i selen; i
(ii) dokozaheksaenska kiselina (22:6; DHA) i eikosapentaenska kiselina (20:5; EPA); i
(iii) uridin monofosfat (UMP); i
(iv) vitamin B6, vitamin B12 i vitamin B9; i
(v) kolin, sol kolina i/ili ester kolina; i
pri čemu pripravak nadalje sadrži vitamin E, pri čemu stariji ljudski subjekt ima ocjenu mini-mentalnog ispitivanja (MMSE) jednaku ili veću od 24, pri čemu se pripravak subjektu daje enteralno najmanje jednom dnevno tijekom razdoblja od najmanje 2 godine.
2. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što navedeni subjekt ima povećan rizik od oštećene kognitivne i/ili memorijske funkcije.
3. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što navedeni subjekt pati od atrofije mozga zbog smanjivanja mozga tijekom starenja i/ili je u opasnosti od neurodegenerativne bolesti.
4. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što se DHA primjenjuje u količini od najmanje 0.5 g na 100 g, poželjno 0.5 - 5 g na 100 g proizvoda ili na dan.
5. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što se uridin, kao kumulativna količina uridina, deoksiuridina, uridin fosfata, nukleobaze uracila i aciliranih derivata uridina, primjenjuje u količini od 0.1-5 g, poželjno 0.2-2.5 g, poželjnije 0.25-1 g na 100 g proizvoda ili na dan.
6. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što se selen primjenjuje u količini od 0.01 – 0.5 mg, poželjno 0.02 – 0.1 mg na 100 g pripravka ili na dan.
7. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što se vitamin C primjenjuje u količini od 20 do 1000 mg, posebno u rasponu od 30 do 500 mg, točnije u rasponu od 50 do 150 mg po 100 g pripravka ili na dan.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2016/050161 WO2017155387A1 (en) | 2016-03-08 | 2016-03-08 | Method for supporting memory function and/or cognitive function |
| EP17716066.0A EP3426236B1 (en) | 2016-03-08 | 2017-03-08 | Method for supporting memory function and/or cognitive function |
| PCT/NL2017/050140 WO2017155395A1 (en) | 2016-03-08 | 2017-03-08 | Method for supporting memory function and/or cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231584T1 true HRP20231584T1 (hr) | 2024-03-15 |
Family
ID=55861106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231584TT HRP20231584T1 (hr) | 2016-03-08 | 2017-03-08 | Postupak za podršku memorijskoj funkciji i/ili kognitivnoj funkciji |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11123306B2 (hr) |
| EP (2) | EP4285992A3 (hr) |
| JP (2) | JP7000336B2 (hr) |
| CN (1) | CN109069446A (hr) |
| BR (1) | BR112018068072A2 (hr) |
| ES (1) | ES2965339T3 (hr) |
| FI (1) | FI3426236T3 (hr) |
| HR (1) | HRP20231584T1 (hr) |
| PL (1) | PL3426236T3 (hr) |
| PT (1) | PT3426236T (hr) |
| SI (1) | SI3426236T1 (hr) |
| WO (2) | WO2017155387A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023041776A1 (en) | 2021-09-17 | 2023-03-23 | N.V. Nutricia | Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088129A1 (en) | 2001-04-26 | 2002-11-07 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline |
| PL209031B1 (pl) | 2001-04-30 | 2011-07-29 | Trommsdorff Arzneimittel | Estry urydyny, ich zastosowanie i sposób wytwarzania, oraz kompozycje farmaceutyczne je zawierające |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| AU2006251569B2 (en) * | 2005-05-23 | 2012-06-21 | Massachusetts Institute Of Technology | Compostions containing pufa and/or uridine and methods of use thereof |
| ATE509624T1 (de) * | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| WO2009002145A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
| WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
| PL2609812T3 (pl) * | 2007-12-20 | 2019-02-28 | N.V. Nutricia | Ciekły produkt zawierający nukleotydy/nukleozydy |
| WO2012125020A1 (en) | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
| WO2013129914A1 (en) * | 2012-03-02 | 2013-09-06 | N.V. Nutricia | Method for improving functional synaptic connectivity |
| CN104144691A (zh) * | 2012-03-02 | 2014-11-12 | N·V·努特里奇亚 | 改善功能突触连通性的方法 |
| WO2013149384A1 (en) * | 2012-04-05 | 2013-10-10 | Nippon Suisan Kaisha, Ltd. | Brain atrophy prevention agent |
| GB201405033D0 (en) * | 2014-03-20 | 2014-05-07 | Isis Innovation | Combination therapy |
| WO2016083362A1 (en) * | 2014-11-25 | 2016-06-02 | Fonden For Helene Elsass Centeret | Composition for improving cognitive functions |
-
2016
- 2016-03-08 WO PCT/NL2016/050161 patent/WO2017155387A1/en active Application Filing
-
2017
- 2017-03-08 BR BR112018068072A patent/BR112018068072A2/pt not_active Application Discontinuation
- 2017-03-08 CN CN201780028115.3A patent/CN109069446A/zh active Pending
- 2017-03-08 ES ES17716066T patent/ES2965339T3/es active Active
- 2017-03-08 PT PT177160660T patent/PT3426236T/pt unknown
- 2017-03-08 WO PCT/NL2017/050140 patent/WO2017155395A1/en active Application Filing
- 2017-03-08 EP EP23191395.5A patent/EP4285992A3/en active Pending
- 2017-03-08 SI SI201731457T patent/SI3426236T1/sl unknown
- 2017-03-08 HR HRP20231584TT patent/HRP20231584T1/hr unknown
- 2017-03-08 PL PL17716066.0T patent/PL3426236T3/pl unknown
- 2017-03-08 FI FIEP17716066.0T patent/FI3426236T3/fi active
- 2017-03-08 EP EP17716066.0A patent/EP3426236B1/en active Active
- 2017-03-08 JP JP2018547886A patent/JP7000336B2/ja active Active
- 2017-03-08 US US16/083,399 patent/US11123306B2/en active Active
-
2021
- 2021-08-11 US US17/399,160 patent/US11918546B2/en active Active
- 2021-12-23 JP JP2021208951A patent/JP7230166B2/ja active Active
-
2024
- 2024-01-23 US US18/419,590 patent/US20240156748A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI3426236T1 (sl) | 2024-02-29 |
| US20240156748A1 (en) | 2024-05-16 |
| JP7230166B2 (ja) | 2023-02-28 |
| JP7000336B2 (ja) | 2022-02-04 |
| US11123306B2 (en) | 2021-09-21 |
| CN109069446A (zh) | 2018-12-21 |
| EP3426236B1 (en) | 2023-10-04 |
| WO2017155387A1 (en) | 2017-09-14 |
| PL3426236T3 (pl) | 2024-03-18 |
| BR112018068072A2 (pt) | 2019-01-08 |
| US20190070126A1 (en) | 2019-03-07 |
| EP4285992A3 (en) | 2024-03-06 |
| EP4285992A2 (en) | 2023-12-06 |
| ES2965339T3 (es) | 2024-04-12 |
| US11918546B2 (en) | 2024-03-05 |
| WO2017155395A1 (en) | 2017-09-14 |
| JP2019512487A (ja) | 2019-05-16 |
| JP2022058393A (ja) | 2022-04-12 |
| EP3426236A1 (en) | 2019-01-16 |
| PT3426236T (pt) | 2023-12-04 |
| US20210386682A1 (en) | 2021-12-16 |
| FI3426236T3 (fi) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DiGiacomo et al. | Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study | |
| EP2170316B1 (en) | Improving memory in subjects with mini-mental state examination of 24-26 | |
| RU2667968C2 (ru) | Способ улучшения функциональной синаптической связи | |
| NZ600740A (en) | Compositions containing pufa and/or uridine and methods of use thereof | |
| RU2014121891A (ru) | Улучшение узнавания | |
| RU2017119470A (ru) | Способ лечения нейротравмы | |
| JP2010531351A5 (hr) | ||
| JP2019520856A5 (hr) | ||
| HRP20201221T1 (hr) | Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu | |
| US20170157164A1 (en) | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly | |
| HRP20231115T1 (hr) | Postupak liječenja atrofije mozga | |
| HRP20231584T1 (hr) | Postupak za podršku memorijskoj funkciji i/ili kognitivnoj funkciji | |
| EP3219306B1 (en) | Composition comprising citicoline and homotaurine for preventing and treating neuodegenerative diseases and cognitive disorders | |
| FI3634396T3 (fi) | Koostumus L-DOPA-hoidon tehon parantamiseen | |
| EP3364962B1 (en) | Method for improving recognition and/or working memory in hyperphenylalaninemia and phenylketonuria patients | |
| DE202017104119U1 (de) | Präparat und Anwendung zur Aufrechterhaltung kognitiver Fähigkeiten von Menschen, insbesondere für unter einer Verminderung ihrer kognitiven Fähigkeiten leidende Menschen und/oder als Prophylaxe | |
| US20170157163A1 (en) | Method for treating, stabilizing or slowing down brain glucose metabolism deficit |